Shunji Haruta, Ph.D., was appointed TR Company Vice President in April 2019, and he has been a Corporate Officer and a General Manager of the Company since January 2011. Dr. Haruta also currently serves as a member of the Board of Directors of SNLD Co., Ltd., a subsidiary of Shin Nippon Biomedical Laboratories. Dr. Haruta joined Shin Nippon Biomedical Laboratories Ltd. in April 2001, to develop the proprietary nasal drug delivery technology which was the first project in SNBL’s translation research business. Dr. Haruta has contributed as an inventor creating numerous patents related to nasal drug delivery technology. New business based on the nasal drug delivery technology has steadily progressed by his dedicated efforts for over 20 years and as a result four instances of technology out-licensing have been achieved, so far. Prior to joining Shin Nippon Biomedical Laboratories Ltd., Dr. Haruta accumulated clinical experience as a clinical pharmacist at Miyazaki Medical College. Dr. Haruta received his Ph.D. degree from the Faculty of Pharmaceuticals Sciences at Okayama University.